These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7560253)

  • 41. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
    Giani P; Landolina M; Giudici V; Bianchini C; Ferrario G; Marchi S; Riva E; Latini R
    Eur J Clin Pharmacol; 1988; 34(2):187-94. PubMed ID: 3383990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.
    Joannides R; Moore N; Iacob M; Compagnon P; Lerebours G; Menard JF; Thuillez C
    Br J Clin Pharmacol; 2006 Feb; 61(2):127-37. PubMed ID: 16433867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of kinetic interactions of nadolol and propranolol with cimetidine.
    Duchin KL; Stern MA; Willard DA; McKinstry DN
    Am Heart J; 1984 Oct; 108(4 Pt 2):1084-6. PubMed ID: 6148867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
    Heuer H; Gülker H; Hasfeld M; Frenking B; Behrenbeck T
    Z Kardiol; 1987 Jul; 76(7):415-20. PubMed ID: 3673163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemically modified cardiac Na+ channels and their sensitivity to antiarrhythmics: is there a hidden drug receptor?
    Benz I; Kohlhardt M
    J Membr Biol; 1994 May; 139(3):191-201. PubMed ID: 7745598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers.
    Hall ST; Harding SM; Hassani H; Keene ON; Pellegatti M
    J Cardiovasc Pharmacol; 1991; 18 Suppl 11():S13-7. PubMed ID: 1725444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative bioavailability of propafenone after administration of a magistral suspension vs. commercial tablets in healthy volunteers.
    Juárez Olguín H; Flores Pérez C; Ramírez Mendiola B; Barranco Garduño L; Sandoval Ramírez E; Flores Pérez J
    Arzneimittelforschung; 2009; 59(3):117-20. PubMed ID: 19402341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma concentration-response relationships of two formulations of propranolol.
    DeLeve LD; Endrenyi L; Leenen FH
    J Clin Pharmacol; 1985 Apr; 25(3):182-6. PubMed ID: 3998198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and metabolism of the antiarrhythmic agent [3H]-diprafenone in the rat.
    Brunner F; Kolmayr U; Kukovetz WR
    Arzneimittelforschung; 1989 Nov; 39(11):1430-5. PubMed ID: 2619776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans.
    Ishizaki T; Horai Y; Kubota K; Minegishi A; Echizen H; Chiba K
    Clin Pharmacol Ther; 1987 Nov; 42(5):525-34. PubMed ID: 3677541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.
    Garg DC; Jallad NS; Mishriki A; Chalavarya G; Kraml M; Fencik M; Weidler DJ
    J Clin Pharmacol; 1987; 27(5):390-6. PubMed ID: 3693583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of disposition and effect of timolol and propranolol on exercise tachycardia.
    Ishizaki T; Tawara K
    Eur J Clin Pharmacol; 1978 Nov; 14(1):7-14. PubMed ID: 32043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH; Sioufi A; Preiswerk G; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The effect of some antiarrhythmic drugs on systolic time intervals in normal subjects (author's transl)].
    Breithardt G; Jochum E; Kuhn H; Seipel L
    Z Kardiol; 1978 Oct; 67(10):6,0-7. PubMed ID: 366939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interaction between propafenone and metoprolol.
    Wagner F; Kalusche D; Trenk D; Jähnchen E; Roskamm H
    Br J Clin Pharmacol; 1987 Aug; 24(2):213-20. PubMed ID: 3620296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereoselective hemodynamic effects of (R)-and (S)-propranolol in man.
    Stoschitzky K; Lindner W; Rath M; Leitner C; Uray G; Zernig G; Moshammer T; Klein W
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):474-8. PubMed ID: 2739756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct separation of the enantiomers of propafenone, diprafenone and their major metabolites by high-performance liquid chromatography on modified cellulose and amylose chiral stationary phases.
    Hollenhorst T; Blaschke G
    J Chromatogr; 1991 Nov; 585(2):329-32. PubMed ID: 1804845
    [No Abstract]   [Full Text] [Related]  

  • 60. Lack of clinically significant beta-blocking effect of propafenone.
    Cheriex EC; Krijne R; Brugada P; Heymeriks J; Wellens HJ
    Eur Heart J; 1987 Jan; 8(1):53-6. PubMed ID: 2880719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.